Fukuoka Noriyasu, Tsukamoto Toyohisa, Uno Junji, Kimura Michio, Morita Shushi
Department of Hospital Pharmacy, Kagawa Medical University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
Yakugaku Zasshi. 2003 Jan;123(1):35-42. doi: 10.1248/yakushi.123.35.
The effects of concomitant antiepileptic drugs on the serum carbamazepine concentration (C1) were analyzed quantitatively. Primidone (PRM), phenobarbital (PB), phenytoin (PHT), valproic acid (VPA), zonisamide (ZNS), clonazepam (CZP), and ethosuximide (ETS) were coadministered with carbamazepine (CBZ). Routine therapeutic drug monitoring data, obtained from epileptic patients who were treated with the repetitive oral administration of CBZ fine granules/tablets, were used for the analysis. A total of 119 patients were administered CBZ alone, and 91, 39, 19, and 6 patients were coadministered one, two, three, and more than four different antiepileptic drugs, respectively. Using the data obtained from the patients administered CBZ alone, Ct could be expressed approximately as a function of the daily dose per extracellular water volume (D/VECW) as Ct = A(D/VECW)B (A, B: parameter). By comparing the regression line on log Ct vs. log(D/VECW) for CBZ alone with that for CBZ plus another concomitant drug, Ct was thus found to be affected at each definite ratio by PB and PHT, but not by VPA and ZNS. We postulated a model showing that Ct is affected by each concomitant antiepileptic drug i at each definite ratio. We defined the parameter Ri(i = 1, 2, ..., 7) representing the effect of each concomitant antiepileptic drug on Ct. A linear polynomial expression, in which both members of this model are converted into common logarithms, was used for a multiple regression analysis. The analysis clarified that PB and PHT lowered Ct to 0.770 and 0.710 the value of CBZ alone, respectively. On the other hand, VPA and ZNS did not affect Ct. The number of patients coadministered PRM, CZP, and/or ETS was not sufficient to detect the effect on Ct based on a test of significance. In the case of the addition or discontinuation of concomitant antiepileptic drugs in the same patient, the estimated Ct values were calculated using the value of each Ri and compared with the measured Ct values. Both values were in good agreement, and thus our results appear valid.
定量分析了联合使用抗癫痫药物对血清卡马西平浓度(C1)的影响。将扑米酮(PRM)、苯巴比妥(PB)、苯妥英(PHT)、丙戊酸(VPA)、唑尼沙胺(ZNS)、氯硝西泮(CZP)和乙琥胺(ETS)与卡马西平(CBZ)联合使用。分析采用了常规治疗药物监测数据,这些数据来自接受CBZ细颗粒/片剂重复口服治疗的癫痫患者。共有119例患者单独服用CBZ,分别有91、39、19和6例患者联合使用了1种、2种、3种和4种以上不同的抗癫痫药物。利用单独服用CBZ患者的数据,C1可近似表示为每细胞外液体积每日剂量(D/VECW)的函数,即C1 = A(D/VECW)B(A、B为参数)。通过比较单独服用CBZ时log C1与log(D/VECW)的回归线和CBZ加另一种联合药物时的回归线,发现PB和PHT以各自确定的比例影响C1,但VPA和ZNS不影响。我们提出了一个模型,表明C1受每种联合抗癫痫药物i以各自确定的比例影响。我们定义了代表每种联合抗癫痫药物对C1影响的参数Ri(i = 1, 2, ..., 7)。使用该模型两边均转换为常用对数的线性多项式表达式进行多元回归分析。分析表明,PB和PHT分别将C1降低至单独使用CBZ时值的0.770和0.710。另一方面,VPA和ZNS不影响C1。联合使用PRM、CZP和/或ETS的患者数量不足以基于显著性检验检测对C1的影响。在同一患者中添加或停用联合抗癫痫药物的情况下,使用每个Ri的值计算估计的C1值,并与测量的C1值进行比较。两者值吻合良好,因此我们的结果似乎有效。